Virtual Humans in Drug Development: Integrating Digital Models with Pharmacological Science
DOI:
https://doi.org/10.22270/ajprd.v13i3.1573Abstract
The conventional pathway of drug development is laborious, costly, and laden with high attrition rates. Recent advances in computational biology have spotlighted the potential of virtual human models, also known as in-silico human avatars, to revolutionize pharmacological research. This review aims to explore the potential of these digital tools in transforming drug discovery and development.These computer-generated, physiology-based simulations replicate biological systems and offer a safe, cost-effective, and ethical alternative for drug testing and disease modeling. In-silico pharmacology allows researchers to perform complex simulations of pharmacokinetics (PK), pharmacodynamics (PD), toxicity, and drug-disease interactions using virtual models that emulate human anatomy and physiology. This approach is increasingly valuable given the ethical constraints of animal testing and the need for accelerated drug discovery timelines. The development of digital twins, which represent the virtual counterpart of real patients, further empowers precision medicine and individualized therapy selection. By integrating artificial intelligence (AI), machine learning (ML), and physiologically based pharmacokinetic (PBPK) models with these avatars, predictive accuracy and the personalization of therapeutic strategies are significantly enhanced.This review discusses the core components, applications, challenges, and regulatory landscapes surrounding virtual human models in drug development.
Downloads
References
Badhe Y, Gupta R, Rai B. Virtual screening of natural compounds as potential inhibitors of SARS-CoV-2 main protease. Bioinformation. 2020;16(5):385–90.
Raj U, Varadwaj PK. Flavonoids as potential inhibitors against SARS-CoV-2 main protease. Bioinformation. 2020;16(3):236–42.
Anwar S, Wahid B. In silico analysis of pharmacokinetic properties of repurposed drugs against SARS-CoV-2. Bioinformation. 2020;16(6):426–31.
Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the “bottom up” and “top down” approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79(1):48–55.
Musuamba FT, Skottheim Rusten I, Lesage R, de Béthune MP. Model-informed drug development in the era of precision medicine: state of the art and future trends. CPT Pharmacometrics Syst Pharmacol. 2021;10(2):120–4.
Viceconti M, Hunter P, Hose R. Big data, big knowledge: big data for personalized healthcare. IEEE J Biomed Health Inform. 2015;19(4):1209–15.
Hunter P, Viceconti M. The VPH-Physiome Project: standards and tools. Interface Focus. 2013;3(2):20120081.
Ghosh S, Maiti S. Virtual screening and drug design: computational chemistry approaches for lead discovery. Bioinformation. 2022;18(7):584–90.
Zhang Q, Liu T, Ng DW, Xu L. A machine learning-based drug repositioning framework for combating COVID-19. Bioinformation. 2020;16(6):470–8.
Guo Y, et al. Integration of systems biology and virtual human modeling to assess cancer therapies. Curr Pharm Des. 2014;20(30):4956–65.
Crampin EJ, Smith NP, Hunter PJ. Multi-scale modelling and the IUPS Physiome Project. J Mol Histol. 2004;35(7):707–14.
Musuamba FT, et al. Challenges in using modeling approaches in pediatric drug development. Front Pediatr. 2021;9:642447.
Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646–56.
Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.
Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259–67.
Corral-Acero J, et al. The ‘digital twin’ to enable the vision of precision cardiology. Eur Heart J. 2020;41(48):4556–64.
Hege HC, et al. Modeling blood flow and oxygen transport in virtual human organs. Acta Numer. 2018;27:103–90.
Sakharkar MK, Sakharkar KR. Predicting therapeutic targets by computational gene network analysis. Bioinformation. 2013;9(8):396–402.
Sathe A, et al. Identification of potential novel targets for colorectal cancer using network pharmacology and molecular docking. Bioinformation. 2021;17(3):327–36.
Woodhead JL, et al. Analyzing the mechanism of drug-induced liver injury with DILIsym®. Clin Pharmacol Ther. 2017;101(4):490–8.
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1(9):e6.
European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2018. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf
US FDA. Physiologically Based Pharmacokinetic Analyses – Format and Content Guidance for Industry. 2018. Available from: https://www.fda.gov/media/101469/download
Sakharkar KR, Sakharkar MK. Artificial intelligence in drug development. Bioinformation. 2020;16(4):301–4.
Liu X, et al. Applications of PBPK modeling and simulation in regulatory decision making and its influence on drug development. J Clin Pharmacol. 2020;60(S1):S3–17.
Agrawal R, et al. A review on predictive modeling of COVID-19 using AI. Bioinformation. 2020;16(3):288–94.
Polasek TM, et al. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualised dosing at scale. Clin Pharmacokinet. 2018;57(5):665–76.
Jain S, Patel A, Chauhan N. Computational modeling in cardiovascular medicine. Bioinformation. 2021;17(8):697–702.
Mukherjee R, Satyanarayana U, Neogi S. Systems biology approach in metabolic disease modeling. Bioinformation. 2015;11(7):342–6.
Pant K, Yadav AK. Digital twin in healthcare: concept, architecture, and challenges. Bioinformation. 2021;17(9):810–6.
Viceconti M, Hunter P. The Virtual Physiological Human: ten years after. Annu Rev Biomed Eng. 2016;18:103–23.
Eissing T, Kuepfer L, Becker C, et al. A model-based approach to dose selection and efficacy prediction in early clinical drug development. CPT Pharmacometrics Syst Pharmacol. 2011;1(1):e13.
Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013–34.
Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. Brief Bioinform. 2019;20(5):1699–708.
Kovatchev B, Breton M, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009;3(1):44–55.
Allen RJ, Eissing T, Lippert J. Modeling and simulation for pediatric drug development. Clin Pharmacol Ther. 2016;100(4):362–75.
Henney AM, Coaker SJ, Gavaghan DJ. The Virtual Physiological Human: exploring the role of informatics in integrative bioscience. J R Soc Interface. 2008;5(Suppl 3):S131–8.
Musuamba FT, Manolis E, Holford N, et al. Advanced methods for dose exposure–response modeling in drug development: recent trends and perspectives. Br J Clin Pharmacol. 2021;87(6):2197–212.
Vass A, Podhajska A, Kis A, Papp R, Cserey G. Predicting pharmacokinetic parameters from chemical structure using deep learning. J Cheminform. 2021;13(1):1–14.
Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug research and development. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):69–76.
Pappalardo F, Pennisi M, Ricupito A, Viceconti M. Agent-based modeling and simulation in computational immunology. Immunol Rev. 2014;261(1):134–47.
Chary KVK, Ramanathan M, Rajkumar J. Application of artificial intelligence in drug discovery and development. Biomed Pharmacother. 2022;153:113325.
Jeliazkova N, Jeliazkov V, Georgiev I. Tools for read-across and in silico modeling in toxicology. Comput Toxicol. 2021;18:100163.
Lal MA, La Colla L, Bonazzi D, Shorten G, Razi M. Digital health and AI in drug development and personalized care. Nat Rev Drug Discov. 2022;21(11):797–8.
Kotecha K, Garg N. Applications of ML in the pharma industry: a case-based perspective. Expert Opin Drug Discov. 2021;16(10):1115–25.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Mohamed Afsal A, Dhivya G, Gowrishallini P, Devi Sowndarya N, Suprraja S
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.